Latest Breaking News On - Jeffrey delong - Page 1 : comparemela.com

Woman whose boyfriend died in crash urges judge never to allow other driver behind wheel

Woman whose boyfriend died in crash urges judge never to allow other driver behind wheel
wuft.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wuft.org Daily Mail and Mail on Sunday newspapers.

United statesBradford countyAlachua countyWilliam davisAlaina johnsonFreddie lee slaterAaron kelleyLincoln towncarJeffrey delongCounty road

Stock Traders Purchase Large Volume of Put Options on Apellis Pharmaceuticals (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) saw some unusual options trading activity on Tuesday. Stock traders bought 7,254 put options on the company. This represents an increase of 401% compared to the typical volume of 1,447 put options. Analyst Ratings Changes A number of equities analysts recently commented on APLS shares. Wedbush decreased their […]

New yorkUnited statesAlec machielsBanque pictet cieRaymond jamesPictet cie europeMark jeffrey delongYork state common retirement fundSecurities exchange commissionCredit suisse groupApellis pharmaceuticals stock performanceApellis pharmaceuticals company profileApellis pharmaceuticalsApellis pharmaceuticals incDupont capital management corpNews ratings for apellis pharmaceuticals daily

Virginia Retirement Systems ET AL Raises Position in Apellis Pharmaceuticals, Inc (NASDAQ:APLS)

Virginia Retirement Systems ET AL increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) by 7.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,000 shares of the company’s stock after purchasing an additional 400 shares during the […]

United statesAlec machielsStifel nicolausPictet cie europeMark jeffrey delongRobertw bairdInvestment advisorsSecurities exchange commissionApellis pharmaceuticals profile get ratingCredit suisse groupAlphacrest capital managementIntelligence driven advisersApellis pharmaceuticalsApellis pharmaceuticals incQuarter for apellis pharmaceuticalsGoldman sachs group

FY2025 EPS Estimates for Apellis Pharmaceuticals, Inc Decreased by Oppenheimer (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) – Analysts at Oppenheimer reduced their FY2025 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a research report issued to clients and investors on Thursday, April 21st. Oppenheimer analyst J. Kim now forecasts that the company will post earnings of $4.72 per share for the year, down […]

United statesThomson reuterRaymond jamesLukas scheiblerMark jeffrey delongHarbor investment advisoryLife insurance coInvestors servicesSwiss national bankJpmorgan chase coApellis pharmaceuticals get ratingApellis pharmaceuticalsApellis pharmaceuticals incGoldman sachs groupGet ratingInvestment advisory

Brokerages Expect Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Will Announce Quarterly Sales of $12 81 Million

Analysts expect Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) to post sales of $12.81 million for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for Apellis Pharmaceuticals’ earnings, with estimates ranging from $11.13 million to $13.70 million. The firm is expected to issue its next quarterly earnings results on Monday, […]

Alec machielsRaymond jamesMark jeffrey delongRobertw bairdGeode capital managementSecurities exchange commissionZacks investment researchPerceptive advisorsBlackrock incNeedham companyJpmorgan chase coApellis pharmaceuticals get ratingApellis pharmaceuticalsApellis pharmaceuticals incVictory capital management incMacquarie group ltd